Biotum

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biotum

The Biotum product is a highly specialized injectable medication used for its powerful ability to combat severe bacterial infections. Its identity and core function are rooted in its specific active ingredient and its classification as a cornerstone beta-Lactam antibiotic.


Quick Facts: Biotum (Ceftazidime)

Property Description
Active ingredient Ceftazidime
Form Sterile powder for solution for injection
Pharmacological class Third-generation cephalosporin antibiotic
General purpose Treating severe systemic bacterial infections
Origin Semisynthetic beta-Lactam derivative

Identity and Classification: Biotum as a Cephalosporin

Biotum contains the single active ingredient Ceftazidime, which is scientifically classified as a semisynthetic beta-Lactam derivative and a third-generation cephalosporin antibiotic. This medication belongs to the broader beta-Lactam class, recognized for its potent antibacterial agent properties. Ceftazidime is recognized for its role in managing serious infections. Its differentiating feature within the cephalosporin family is its superior efficacy against many Gram-negative pathogens, a property clinically recognized as essential for treating hospital-acquired infections where resistance patterns are often complex.

Composition, Form, and General Purpose

The medication is supplied exclusively as a sterile powder for solution for injection, a parenteral formulation that contains Ceftazidime typically as the pentahydrate salt. This form requires reconstitution with a sterile solvent just prior to administration. The core purpose of Biotum is to provide a potent, reliable antibacterial agent for combating serious systemic infections. The drug's action is fundamentally bactericidal, rapidly killing susceptible bacteria by inhibiting their cell wall formation. Ceftazidime is primarily employed against various serious Gram-negative and Gram-positive infections in hospitalized patients, often used in scenarios requiring empiric broad-spectrum coverage. This confirms that the medication is reserved for significant, severe infections requiring a highly effective, fast-acting treatment regimen.

Regulatory References

  1. Ceftazidime entry on the WHO EML

What side effects are possible with Biotum?

Possible Side Effects and Safety Information

Biotum, whose primary component is Dimethyl Sulfoxide ( DMSO), carries safety information based on both its chemical handling characteristics and documented adverse reactions from clinical applications of DMSO.

Key Adverse Reactions

Side effects are most commonly reported upon contact or administration and are often dependent on the dose or exposure level. Serious reactions are rare but have been reported, particularly with high-concentration or high-dose exposure.

System-Organ Class Common Adverse Reactions (Clinical Use) Exposure-Related Effects (Chemical Handling)
Gastrointestinal Nausea, vomiting, abdominal cramps, diarrhea. May be harmful if swallowed.
Skin and Tissue Garlic-like odor on breath and skin, skin irritation, burning, itching, redness, blistering. May cause skin irritation and is potentially harmful if absorbed through the skin.
Nervous System Headache, dizziness, sedation, drowsiness. Headache, dizziness, sedation (associated with large exposure).
Other Hypotension (low blood pressure), bradycardia (slow heart rate), nasal congestion. May cause eye and respiratory tract irritation.

Safety Considerations and Limitations

Serious Adverse Reactions: Although most reactions are transient and mild, severe allergic reactions, cardiac events (e.g., severe bradycardia, cardiac arrest), and a breakdown of red blood cells (hemolysis) have been reported, primarily associated with high-concentration intravenous administration, such as during stem cell cryopreservation procedures.

Interactions: As a potent penetration enhancer, DMSO can increase the absorption of other topical medications, potentially increasing their effects or side effects. It may also interact with blood thinners, steroids, and heart medications.

Population-Specific Warnings: Official safety notes advise against the use of DMSO during pregnancy and breastfeeding, as sufficient data on the potential effects on the fetus or infant are unavailable.

Regulatory Status: Prescription-grade DMSO is approved by the U.S. Food and Drug Administration ( FDA) for one specific medical indication (intravesical use for interstitial cystitis). Non-prescription or industrial-grade DMSO products, which may contain impurities, are not approved for human use and carry additional risks.

Overdose and Emergency Response

The official regulatory profile for Biotum (Ceftazidime) focuses on the potential for neurotoxicity resulting from high concentrations of the drug.

Documented Overdose Manifestations

Documented overdose presentations involve severe Central Nervous System (CNS) manifestations, including seizure activity (convulsions), encephalopathy, asterixis (flapping tremor), neuromuscular excitability, and coma. These events are officially recognized as potential life-threatening neurological sequelae or severe outcomes.

Population-Specific Overdose Notes

Overdosage is frequently linked to inadequate drug clearance and is specifically noted in patients with impaired renal function. This condition represents a critical risk note, as failure to adjust the dosage leads to the high plasma concentrations associated with toxicity.

Emergency Actions and Supportive Measures

In the event of an acute overdosage, regulatory documents mandate that the patient be placed under careful observation and receive supportive treatment. Immediate medical attention must be sought when any severe CNS symptoms are observed. While no specific antidote is known, procedural interventions such as hemodialysis or peritoneal dialysis may be used to aid in the removal of Ceftazidime from the body.

Therapeutic Uses of Biotum

What Biotum Treats: Main Uses and Benefits

Biotum is relevant for addressing severe, systemic bacterial infections where necessary therapeutic support is essential for patient outcome. Its core purpose is to address the source of the infection in challenging clinical scenarios, which is consistent with general guidelines for this class of medication.

This medication is applied in clinical settings that involve acute or unstable symptom patterns, commonly used across conditions presenting with acute episodes. These include septicemia (bloodstream infections), bacterial meningitis, hospital-acquired pneumonia, complicated urinary tract infections, and acute infections in the bone and joints.

“In the clinical setting, this medication provides supportive short-term symptomatic assistance when patients experience heightened systemic burden due to aggressive bacterial presence.”


Therapeutic Contexts and Patient Benefit

Biotum is relevant for managing complicated infections, including those involving organisms such as Pseudomonas aeruginosa, often encountered in situations marked by temporary physiological imbalance. It is also commonly used for vulnerable groups, such as patients with febrile neutropenia or individuals with cystic fibrosis experiencing acute flare-ups. This focused action supports the patient during difficult episodes by easing distress and helps maintain a sense of stability when symptoms are more noticeable, contributing to improved comfort during symptomatic periods.


Quick Fact: Relief for Systemic Stress
Primary Goal: Addressing the bacterial source to help manage symptoms related to systemic imbalance, such as fever and profound distress.
Typical Scenario: Applied when symptoms interfere with daily functioning in patients with severe, acute episodes.

Regulatory References

  1. U.S. National Library of Medicine (NIH) MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility for Biotum (Ceftazidime) is determined by official regulatory criteria, defining populations who are absolutely prohibited from use and those who require conditional monitoring.

Contraindicated Populations

Biotum must not be used if a patient has a known hypersensitivity to ceftazidime, the cephalosporin class, or any other beta-lactam antibacterial agent (e.g., penicillins), as this poses an absolute contraindication.

Condition-Specific Eligibility Rules

Population Status Regulatory Rule (Based on Official Labeling)
Renal Impairment Mandatory dosage reduction is required for patients with impaired renal function (CrCl le 50 mL/min) to prevent potential neurological sequelae.
Hepatic Impairment No dosage adjustment is required for patients with mild or moderate liver dysfunction.
Gastrointestinal History Use requires caution in patients with a history of gastrointestinal disease, particularly colitis.

Age and Reproductive Status

  • Age Groups: Adults and pediatric patients, including neonates (from birth), are generally eligible. Use in older adults (typically ge 80 years) has a recommended maximum daily dose due to reduced physiological clearance.
  • Pregnancy and Lactation: Use during pregnancy is conditional, recommended only if the clinical benefit outweighs the potential risk. The medicine is excreted into human milk in small quantities, but adverse effects on the breastfed infant are not anticipated at therapeutic doses.

What should I know about interactions with other medicines?

Biotum Interactions with other medicines and products

Biotum can interact with other medicinal products by affecting drug metabolism and transport pathways, or through combined pharmacodynamic effects.


Key Interaction Categories

Mechanism / Substance Class Interaction Outcome Management Classification
Potent CYP3A4 Inducers (e.g., rifampicin, St. John’s Wort, phenytoin, carbamazepine) Significantly decreased Biotum concentration. Contraindicated
Potent CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) Increased Biotum exposure. Use with Caution/Monitoring
Medicines Prolonging the QT Interval (e.g., certain antiarrhythmics, macrolides) Risk of additive effect on heart rhythm. Use with Caution/Monitoring
Sensitive CYP3A4 or P-gp Substrates (e.g., midazolam, digoxin, cyclosporine) Increased concentration of the co-administered drug. Requires Dose Adjustment/Monitoring
Calcium-Containing Products (Intravenous) Risk of precipitation in the bloodstream. Contraindicated (IV use)
Highly Protein-Bound Medicines (e.g., warfarin) Potential for displacement, altering the co-administered drug's effects. Requires Monitoring

Interaction Notes

The most significant pharmacokinetic interactions for Biotum involve the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein (P-gp) efflux transporter, as Biotum is a substrate and mild inhibitor of CYP3A4 and a P-gp substrate. Co-administration with strong CYP3A4 inducers is explicitly prohibited to prevent therapeutic failure due to reduced Biotum levels. Caution and close monitoring are necessary when co-administering Biotum with medicines that inhibit these same pathways or share the risk of prolonging the QT interval. Intravenous use of Biotum must be avoided with intravenous calcium-containing solutions to prevent a dangerous precipitation reaction.

Mechanism of Action

Irreversible Covalent Binding to Penicillin-Binding Proteins (PBPs)

Biotum's mechanism is defined by the active ingredient, Ceftazidime, which functions as an irreversible covalent inhibitor of bacterial enzymes known as Penicillin-Binding Proteins (PBPs). The drug's beta-lactam structure mimics the D-Ala-D-Ala terminus of the peptidoglycan precursor, allowing it to form a stable covalent bond with the PBP active site via acylation. This molecular interaction immediately inactivates the enzyme, initiating the cellular cascade that results in the bactericidal effect.

Mechanistic Cascade Resulting in Bacterial Cell Wall Lysis

Inhibition of PBPs disrupts the final cross-linking step of peptidoglycan synthesis, leading to a critical failure of the bacterial cell wall structure. The cell can no longer maintain its structural integrity against internal osmotic pressure, which, combined with the activation of bacterial autolytic enzymes, triggers bacteriolysis (cell rupture and death). This physiological consequence constitutes the mechanism's defined bactericidal activity.

️ Functional Constraints: beta-Lactamase Inactivation

The mechanism's efficacy is biologically constrained by the presence of certain bacterial beta-Lactamase enzymes, which can hydrolyze the drug's beta-lactam ring, resulting in inactivation. Furthermore, reduced binding affinity due to modified PBP structures limits the drug's action, defining the scope of microbes susceptible to the mechanism.

Dosage and Administration Information

Official Administration Guidelines for Biotum

Biotum is an injectable medication that must be administered only by a trained healthcare professional in a medical setting, such as a clinic or hospital, via the Intravenous (IV) or Intramuscular (IM) route. This product is not intended for self-administration at home.

Dosing and Frequency

Administration frequency is typically daily and must follow the specific dose and regimen determined by the prescribing doctor. The exact dosage is highly individualized, depending on the severity of the condition, patient response, and other individual factors. It is critical to complete the full, prescribed course of treatment, even if symptoms begin to improve.

Administration Scope Official Requirement
Route Intravenous (IV) or Intramuscular (IM) injection.
Timing Administer at regular intervals daily, as prescribed.
Preparation None explicitly documented for patient preparation; professional handling required.

Special Patient Populations and Missed Doses

  • Pediatric Use: Use of Biotum is generally not recommended in children under 18 years of age. Decisions regarding use in this population require specialized medical consultation.
  • Missed Dose: If a dose is missed, it should be received as soon as the patient remembers. However, if it is nearly time for the next scheduled dose, the patient should skip the missed dose and resume the normal daily schedule. Double dosing to compensate for a missed dose is not permitted.

No specific instructions regarding administration with or without food are officially documented for the injectable route.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biotum (Ceftazidime)


Evidence for Severe Lung and Respiratory Infections

Biotum has been studied for severe infections affecting the lungs, specifically hospital-acquired pneumonia (HAP), including its form linked to breathing machines, ventilator-associated pneumonia (VAP). The core of this research involves Randomized Controlled Trials (RCTs), where Biotum was evaluated in comparison to other established antibiotics. These studies included hospitalized adults and older adults who often had severe overall illness, and also included some pediatric patients who were 3 months of age.

Research has examined specific outcomes related to systemic or functional imbalance, such as whether the patients’ symptoms resolved. Trials also monitored the microbiological eradication of the target bacteria from cultures and tracked all-cause mortality over a defined period. Findings describe patterns observed in the studies regarding symptom resolution and the measured clearance of bacteria from the lungs.


Evidence for Complicated Urinary Tract and Abdominal Infections

The evidence base for treating complex infections in the urinary tract and abdomen primarily relies on Randomized Controlled Trials (RCTs) and supporting Systematic Reviews. For complicated urinary tract infections (cUTI), including pyelonephritis, Biotum was studied for both adults and children 3 months of age. Studies examined outcomes related to physical discomfort (symptom resolution) and measured the successful microbiological eradication of the bacteria causing the infection.

For complicated intra-abdominal infections (cIAI), such as peritonitis, research also consists of comparative trials. These studies generally used Biotum in combination with a medicine that covers other types of bacteria (anaerobic bacteria) to cover the necessary range of target pathogens. Findings describe patterns observed in the studies concerning the rates of resolution of both cUTI and cIAI symptoms at the designated follow-up assessments.


Research Focus on Life-Threatening Systemic Conditions

Biotum was evaluated in studies focused on acute, serious systemic conditions, including patients with a fever and low white blood cell count (febrile neutropenia) and patients with bloodstream infections (bacteremia or septicemia). This research often involves RCTs comparing different initial treatment regimens and supported by pooled data from Meta-analyses. These studies focus on critical outcomes monitoring physiological strain or stress.

Key measurements monitored in these trials include the time to defervescence (how long it took for the fever to go down) and, critically, all-cause mortality, which was typically tracked at 30 days post-treatment start. Research highlights changes measured during the study period related to the resolution of the systemic condition.


Research Gaps and Areas of Uncertainty

A primary limitation in the current evidence landscape is that the monotherapy data requires ongoing re-evaluation due to the continuing emergence of bacterial resistance. Consequently, the comparative evidence is lacking for Biotum as a single agent in many contemporary settings where highly resistant strains are common.

What remains uncertain is that much of the most recent high-quality research focuses on a combination product, not Biotum as a single agent. This means that characterizing the long-term effects of the monotherapy is subject to evolving resistance patterns. There is also limited information for long-term outcomes that track patients for several months or years after treatment completion.

Key Studies & References

  1. Efficacy and safety of ceftazidime-avibactam in the treatment of complicated intra-abdominal infections (CIAIs) and complicated urinary tract infections (CUTIs): A meta-analysis of randomized controlled trials
  2. Febrile Neutropenia - StatPearls (Ceftazidime use in empiric therapy)
  3. WHO Essential Medicines List (Ceftazidime - WATCH group)

Frequently Asked Questions (FAQ)

Common questions about Biotum (FAQ)


Q: How quickly does Biotum start working?

Biotum is a fast-acting injectable medication. According to official drug information, after the medication is given into a vein (intravenously), the highest concentration in the blood is typically reached within 5 to 30 minutes. If administered into a muscle (intramuscularly), the peak concentration is generally reached in about one hour.


Q: What happens if I stop taking Biotum suddenly?

Regulatory documents emphasize that it is critical to complete the full, prescribed course of treatment, even if symptoms begin to improve. Stopping the medicine early can risk the infection returning or becoming more difficult to treat. Discontinuing Biotum is typically performed under the guidance of a healthcare professional.


Q: Do I need a prescription to get Biotum?

Yes, Biotum is classified as a prescription medication. Official guidelines describe it as an injectable product provided as a sterile powder for solution, which is administered only by a trained healthcare professional in a medical setting. This classification ensures that use is limited to treating serious systemic bacterial infections under proper medical supervision.


Q: Does Biotum interact with common pain relievers like ibuprofen?

Biotum’s interaction information focuses on medicines that involve the CYP3A4 enzyme and P-glycoprotein transporter. While specific common pain relievers are not listed, interactions with highly protein-bound medicines are noted, as this could alter the effects of co-administered drugs. Patients are typically advised to review all medications and potential risks with their prescribing healthcare professional.


Q: Is Biotum safe to take long-term?

Official research evidence notes that there is currently limited information available for long-term outcomes when patients are tracked for several months or years after treatment completion. As Biotum is generally reserved for short-course treatment of severe, acute infections, decisions regarding any extended use are based on clinical review by a healthcare professional.


Q: Is it normal to feel [mild, common side effect] when starting Biotum?

Adverse reactions, such as nausea, vomiting, or diarrhea, are common when starting Biotum, as documented in official safety information. These effects are often transient. The experience of common side effects is typically communicated to the treating healthcare professional, especially if they become persistent or worsen.


Q: Can Biotum affect my ability to drive?

Biotum's safety information lists common nervous system effects, including headache, dizziness, sedation, and drowsiness. Official guidance suggests that the presence of these effects may result in impairment to the ability to safely drive or operate complex machinery.


Q: Is Biotum a controlled substance?

Official federal scheduling information for drugs, such as that provided by the DEA, indicates that Biotum (ceftazidime) is not classified as a controlled substance.


Q: Can Biotum be taken with vitamins or supplements?

Official drug interaction information addresses potent enzyme inducers like St. John's Wort, which can decrease Biotum's concentration. Patients are typically advised to inform their healthcare provider about all concomitant use of vitamins, herbal products, and dietary supplements, as potential interactions with general supplements are not broadly covered in regulatory documents.


Q: Is there a maximum time someone can take Biotum?

The duration of Biotum treatment is highly individualized based on the infection being treated. Official guidelines often recommend continuing therapy for at least two days after the signs and symptoms of infection have cleared. The overall length of treatment is determined by the healthcare professional managing the patient's care.


Q: Does Biotum affect birth control pills?

Regulatory documents suggest that antibiotics in the same class as Biotum may reduce the effectiveness of ethinyl estradiol, a common component found in some oral contraceptive pills. This reduction could potentially increase the risk of an unintended pregnancy or result in breakthrough bleeding. Precautions related to contraceptive effectiveness are typically discussed with a healthcare professional.


Q: How long do the effects of Biotum last after taking a dose?

Official pharmacological data indicates that Biotum has a short elimination time. The average half-life, which is the time it takes for half of the drug to be eliminated from the body, is approximately 1.9 to 2 hours in adults with normal kidney function.


Q: Does Biotum require a special monitoring test while taking it?

Regulatory safety information indicates that Biotum can interfere with the results of certain laboratory tests, specifically those for glucose and the Coombs' test. Furthermore, patients with kidney impairment will require monitoring of renal function to ensure the correct dosage is maintained.


Q: Is Biotum okay for teenagers to use?

Official labeling contains some differing information regarding use in children and adolescents. Administration guidelines suggest Biotum is generally not recommended for children under 18 years of age. However, separate eligibility criteria state that pediatric patients, including neonates, are generally eligible. The determination of appropriateness for use in this age group is typically made by a healthcare specialist.


Q: What does 'contraindications' mean for Biotum?

In regulatory terms, a contraindication is a condition or circumstance that makes the use of a particular treatment improper or absolutely prohibited. For Biotum, this includes having a known hypersensitivity (severe allergic reaction) to ceftazidime, the cephalosporin class, or any other beta-lactam antibiotic.


Q: Does Biotum interact with blood pressure medications?

Official interaction guidance notes that Biotum should be used with caution alongside medicines that prolong the QT interval, as this can create an additive effect on heart rhythm. Certain blood pressure medications may fall into this category or other relevant interaction classes, which may necessitate monitoring by the healthcare team.


Q: What are the signs of a severe allergic reaction to Biotum?

Severe allergic reactions are serious but rare adverse events associated with Biotum. While the official document notes the risk, signs of a severe reaction typically include difficulty breathing, swelling of the face or throat, rash, or hives. In the event of a severe reaction, the patient's condition requires immediate medical assessment.


Q: How does Biotum compare to a placebo in clinical trials?

Studies described in the official research summaries do not typically compare Biotum to a placebo (an inactive substance) because Biotum is used to treat serious, life-threatening infections. Instead, clinical trials usually evaluate Biotum’s effectiveness by comparing it against other established or standard-of-care antibiotics.

How should Biotum be stored and disposed of?

How to Store and Dispose of Biotum?

The storage and disposal of Biotum (Ceftazidime for injection) must align with regulatory requirements to preserve product sterility and potency.


Storage Requirements

The dry powder form must be stored at Controlled Room Temperature, typically between 15 C and 30 C (59 F and 86 F). The product must be protected from light and kept in its dry state. Any premixed frozen solutions must be maintained at or below -20 C. After reconstitution, the liquid solution has a short-term stability period, such as up to 7 days when refrigerated. As with all prescription medications, Biotum must be stored out of the sight and reach of children and pets.


Disposal Instructions

Unused or expired Biotum should be disposed of using a drug take-back program or mail-back envelope. If a take-back program is unavailable, the product must be mixed with an undesirable substance, sealed, and discarded in the household trash. It must not be poured down a sink or flushed down a toilet, as this practice is restricted.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biotum found in:

A-Z Index: